Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21455527 | 0.92 | TBXAS1 (0.35) | TBXAS1PKMAKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL24200110 | 0.88 | TBXAS1 (0.33) | TBXAS1PKM | |
| SCHEMBL21455172 | 0.87 | TBXAS1 (0.35) | TBXAS1PKM | |
| SCHEMBL21455225 | 0.84 | TBXAS1 (0.34) | TBXAS1PKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL24199899 | 0.84 | TBXAS1 (0.35) | TBXAS1PKMAKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL21455145 | 0.84 | TBXAS1 (0.36) | TBXAS1PKMAKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL25894394 | 0.84 | TBXAS1 (0.36) | TBXAS1PKMAKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL25895072 | 0.84 | TBXAS1 (0.37) | TBXAS1PKMAKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL21455148 | 0.84 | TBXAS1 (0.37) | TBXAS1PKMAKR1C3AKR1C2SMN1; SMN2 | |
| SCHEMBL23425579 | 0.82 | TBXAS1 (0.33) | TBXAS1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939658-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |